Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1981 1
1983 3
1984 3
1985 5
1986 9
1987 8
1988 10
1989 10
1990 10
1991 12
1992 25
1993 25
1994 20
1995 32
1996 53
1997 35
1998 34
1999 34
2000 38
2001 52
2002 98
2003 83
2004 75
2005 89
2006 94
2007 101
2008 108
2009 164
2010 134
2011 152
2012 121
2013 133
2014 150
2015 153
2016 192
2017 216
2018 195
2019 224
2020 306
2021 359
2022 330
2023 283
2024 139

Text availability

Article attribute

Article type

Publication date

Search Results

3,796 results

Results by year

Filters applied: . Clear all
Quoted phrase not found in phrase index: "Alzheimer disease 17"
Page 1
Peripheral and central immune system crosstalk in Alzheimer disease - a research prospectus.
Bettcher BM, Tansey MG, Dorothée G, Heneka MT. Bettcher BM, et al. Nat Rev Neurol. 2021 Nov;17(11):689-701. doi: 10.1038/s41582-021-00549-x. Epub 2021 Sep 14. Nat Rev Neurol. 2021. PMID: 34522039 Free PMC article. Review.
Dysregulation of the immune system is a cardinal feature of Alzheimer disease (AD), and a considerable body of evidence indicates pathological alterations in central and peripheral immune responses that change over time. ...To guide the prospectus, we begin with an …
Dysregulation of the immune system is a cardinal feature of Alzheimer disease (AD), and a considerable body of evidence indica …
Effect of Levetiracetam on Cognition in Patients With Alzheimer Disease With and Without Epileptiform Activity: A Randomized Clinical Trial.
Vossel K, Ranasinghe KG, Beagle AJ, La A, Ah Pook K, Castro M, Mizuiri D, Honma SM, Venkateswaran N, Koestler M, Zhang W, Mucke L, Howell MJ, Possin KL, Kramer JH, Boxer AL, Miller BL, Nagarajan SS, Kirsch HE. Vossel K, et al. JAMA Neurol. 2021 Nov 1;78(11):1345-1354. doi: 10.1001/jamaneurol.2021.3310. JAMA Neurol. 2021. PMID: 34570177 Free PMC article. Clinical Trial.
IMPORTANCE: Network hyperexcitability may contribute to cognitive dysfunction in patients with Alzheimer disease (AD). OBJECTIVE: To determine the ability of the antiseizure drug levetiracetam to improve cognition in persons with AD. ...Participants were adults 80 y …
IMPORTANCE: Network hyperexcitability may contribute to cognitive dysfunction in patients with Alzheimer disease (AD). OBJECTI …
Behavioural and psychological symptoms of dementia in patients with Alzheimer's disease and family caregiver burden: a path analysis.
Kim B, Noh GO, Kim K. Kim B, et al. BMC Geriatr. 2021 Mar 5;21(1):160. doi: 10.1186/s12877-021-02109-w. BMC Geriatr. 2021. PMID: 33663416 Free PMC article.
However, the causal relationship between BPSD in community-dwelling patients with Alzheimer's disease (AD) and caregiver burden is yet to be established. ...Factor extraction was performed using principal component analysis, followed by Varimax factor rotation. RESU …
However, the causal relationship between BPSD in community-dwelling patients with Alzheimer's disease (AD) and caregiver burde …
Causal relationship between Alzheimer's disease and cardiovascular disease: a bidirectional Mendelian randomization analysis.
Zhang F, Xian D, Feng J, Ning L, Jiang T, Xu W, Liu Y, Zhao Q, Peng M. Zhang F, et al. Aging (Albany NY). 2023 Sep 2;15(17):9022-9040. doi: 10.18632/aging.205013. Epub 2023 Sep 2. Aging (Albany NY). 2023. PMID: 37665672 Free PMC article.
Observational studies suggest that cardiovascular disease (CVD) increases the risk of developing Alzheimer's disease (AD). ...A higher genetically predicted OR for CES (0.9) (95% CI 0.82-0.99, P = 0.02) was linked to a decreased AD risk. ...
Observational studies suggest that cardiovascular disease (CVD) increases the risk of developing Alzheimer's disease …
Blood neuro-exosomal synaptic proteins predict Alzheimer's disease at the asymptomatic stage.
Jia L, Zhu M, Kong C, Pang Y, Zhang H, Qiu Q, Wei C, Tang Y, Wang Q, Li Y, Li T, Li F, Wang Q, Li Y, Wei Y, Jia J. Jia L, et al. Alzheimers Dement. 2021 Jan;17(1):49-60. doi: 10.1002/alz.12166. Epub 2020 Aug 10. Alzheimers Dement. 2021. PMID: 32776690 Free PMC article.
INTRODUCTION: Exosomes are an emerging candidate for biomarkers of Alzheimer's disease (AD). This study investigated whether exosomal synaptic proteins can predict AD at the asymptomatic stage. ...DISCUSSION: This study revealed that exosomal GAP43, neurogran …
INTRODUCTION: Exosomes are an emerging candidate for biomarkers of Alzheimer's disease (AD). This study investigated whether e …
Trial of Solanezumab for Mild Dementia Due to Alzheimer's Disease.
Honig LS, Vellas B, Woodward M, Boada M, Bullock R, Borrie M, Hager K, Andreasen N, Scarpini E, Liu-Seifert H, Case M, Dean RA, Hake A, Sundell K, Poole Hoffmann V, Carlson C, Khanna R, Mintun M, DeMattos R, Selzler KJ, Siemers E. Honig LS, et al. N Engl J Med. 2018 Jan 25;378(4):321-330. doi: 10.1056/NEJMoa1705971. N Engl J Med. 2018. PMID: 29365294 Free article. Clinical Trial.
BACKGROUND: Alzheimer's disease is characterized by amyloid-beta (Abeta) plaques and neurofibrillary tangles. ...The primary outcome was the change from baseline to week 80 in the score on the 14-item cognitive subscale of the Alzheimer's Disease …
BACKGROUND: Alzheimer's disease is characterized by amyloid-beta (Abeta) plaques and neurofibrillary tangles. ...The primary o …
Effect of aromatherapy on patients with Alzheimer's disease.
Jimbo D, Kimura Y, Taniguchi M, Inoue M, Urakami K. Jimbo D, et al. Psychogeriatrics. 2009 Dec;9(4):173-9. doi: 10.1111/j.1479-8301.2009.00299.x. Psychogeriatrics. 2009. PMID: 20377818 Free article. Clinical Trial.
In the present study, we examined the curative effects of aromatherapy in dementia in 28 elderly people, 17 of whom had Alzheimer's disease (AD). METHODS: After a control period of 28 days, aromatherapy was performed over the following 28 days, with a wash ou …
In the present study, we examined the curative effects of aromatherapy in dementia in 28 elderly people, 17 of whom had Alzheimer …
Medium-chain triglycerides improved cognition and lipid metabolomics in mild to moderate Alzheimer's disease patients with APOE4(-/-): A double-blind, randomized, placebo-controlled crossover trial.
Xu Q, Zhang Y, Zhang X, Liu L, Zhou B, Mo R, Li Y, Li H, Li F, Tao Y, Liu Y, Xue C. Xu Q, et al. Clin Nutr. 2020 Jul;39(7):2092-2105. doi: 10.1016/j.clnu.2019.10.017. Epub 2019 Oct 22. Clin Nutr. 2020. PMID: 31694759 Clinical Trial.
Participants were randomized between two sequences (placebo followed by MCT or MCT followed by placebo) and took MCT jelly or placebo jelly (canola oil) by mouth three times daily (total daily fat dose: 17.3 g MCT, or 19.7 g canola oil) for 30 days per phase. The primary o …
Participants were randomized between two sequences (placebo followed by MCT or MCT followed by placebo) and took MCT jelly or placebo jelly …
Amyloid beta deposition, neurodegeneration, and cognitive decline in sporadic Alzheimer's disease: a prospective cohort study.
Villemagne VL, Burnham S, Bourgeat P, Brown B, Ellis KA, Salvado O, Szoeke C, Macaulay SL, Martins R, Maruff P, Ames D, Rowe CC, Masters CL; Australian Imaging Biomarkers and Lifestyle (AIBL) Research Group. Villemagne VL, et al. Lancet Neurol. 2013 Apr;12(4):357-67. doi: 10.1016/S1474-4422(13)70044-9. Epub 2013 Mar 8. Lancet Neurol. 2013. PMID: 23477989
BACKGROUND: Similar to most chronic diseases, Alzheimer's disease (AD) develops slowly from a preclinical phase into a fully expressed clinical syndrome. ...Our projections suggest a prolonged preclinical phase of AD in which Abeta deposition reaches our threshold o …
BACKGROUND: Similar to most chronic diseases, Alzheimer's disease (AD) develops slowly from a preclinical phase into a fully e …
Probiotic and selenium co-supplementation, and the effects on clinical, metabolic and genetic status in Alzheimer's disease: A randomized, double-blind, controlled trial.
Tamtaji OR, Heidari-Soureshjani R, Mirhosseini N, Kouchaki E, Bahmani F, Aghadavod E, Tajabadi-Ebrahimi M, Asemi Z. Tamtaji OR, et al. Clin Nutr. 2019 Dec;38(6):2569-2575. doi: 10.1016/j.clnu.2018.11.034. Epub 2018 Dec 10. Clin Nutr. 2019. PMID: 30642737 Clinical Trial.
BACKGROUND AND AIMS: Combined probiotic and selenium supplementation may improve Alzheimer's disease (AD) by correcting metabolic abnormalities, and attenuating inflammation and oxidative stress. ...Compared with only selenium and placebo, probiotic and selenium co- …
BACKGROUND AND AIMS: Combined probiotic and selenium supplementation may improve Alzheimer's disease (AD) by correcting metabo …
3,796 results